Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer

9Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

This report details a study conducted to assess the role of VEGF gene polymorphisms in the prognosis of advanced non-small cell lung carcinoma (NSCLC). Samples obtained from 210 advanced NSCLC patients admitted at the Huaihe Hospital of Henan University between January 2010 and December 2011 were recruited for this study. The VEGF -2578C/A (rs699947), +936C/T (rs3025039), and -634G/C (rs2010963) genotypes were analyzed by polymerase chain reaction-restriction fragment length polymorphism. We discovered, by logistic regression analysis, that the TT genotype of VEGF +936C/T was associated with more complete response + partial response to chemotherapy, compared to the CC genotype (odds ratio (OR) = 4.78, 95% confidence interval (CI) = 1.34-25.85). We also found a correlation between the TT genotype of VEGF +936C/T and lower risk of death from all causes compared to the CC genotype (OR = 0.26, 95%CI = 0.10-0.69), using the Cox proportional hazard model (after adjusting for potential confounding factors). In conclusion, we discovered that the VEGF +936C/T gene polymorphism influences the response to chemotherapy and overall survival of NSCLC patients.

Cite

CITATION STYLE

APA

Chen, N., Ma, C. N., Zhao, M., & Zhang, Y. J. (2015). Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer. Genetics and Molecular Research, 14(4), 16006–16011. https://doi.org/10.4238/2015.December.7.13

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free